Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670059 | 0.99 | ADRB2 (0.42) | ADRB2ADRB1ADRB3NFE2L2CYP19A1 | |
| Water SCHEMBL4672111 | 0.99 | ADRB2 (0.42) | ADRB2ADRB1ADRB3NFE2L2CYP19A1 | |
| Water SCHEMBL4673070 | 0.99 | ADRB2 (0.42) | ADRB2ADRB1ADRB3NFE2L2CYP19A1 | |
| SCHEMBL6301320 | 0.97 | ADRB2 (0.41) | ADRB2ADRB1ADRB3NFE2L2CYP19A1 | |
| SCHEMBL4670626 | 0.96 | ADRB2 (0.40) | ADRB2ADRB1ADRB3NFE2L2CYP19A1 | |
| SCHEMBL4670093 | 0.95 | NPSR1 (0.40) | ADRB2ADRB1ADRB3NFE2L2CYP19A1 | |
| SCHEMBL4670052 | 0.94 | ADRB2 (0.38) | ADRB2ADRB1ADRB3NFE2L2CYP19A1 | |
| SCHEMBL4670471 | 0.93 | ADRB2 (0.39) | ADRB2ADRB1ADRB3NFE2L2CYP19A1 | |
| SCHEMBL4677838 | 0.92 | NFE2L2 (0.40) | ADRB2ADRB1ADRB3NFE2L2CYP19A1 | |
| SCHEMBL4670426 | 0.91 | ADRB2 (0.38) | ADRB2ADRB1ADRB3NFE2L2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054881-B1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-6903218-B2 | Sulfonamide substituted chroman derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | LADOUCEUR GAETAN H (US) | 2004-04-15 | — | — | US | disclosed |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | BAYER PHARMACEUTICALS CORPORATION | 2003-04-17 | — | — | US | disclosed |
| EP-1054881-A1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | Bayer Corporation (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6051586-A | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | BAYER CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0858340-A4 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO INC (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999032475-A1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0858340-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997016189-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1997-05-09 | — | — | WO | disclosed |
| US-5561142-A | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity | MERCK & CO., INC. (US) | 1996-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | ADRB2 2/4885ADRB1 3/4885ADRB3 1/4885 |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | ADRB3, ADRB2, ADRB1 | ADRB2 2/4885ADRB1 3/4885ADRB3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.